Enter a keyword or phrase to search all pages in this section:


Advanced search

Archive:

Looking for a previously published document in this section?

Medical Device Alert: ASR™ hip replacement implants manufactured by DePuy International Ltd (MDA/2010/069)

Document details:

Type: Medical Device Alert
Series No: MDA/2010/069
Audience: Healthcare professionals
Published: 7 September 2010 at 13:00
Format: Electronic only
Size: A4
Pages: 5
Price: Free
ISBN/ISSN:
Author:
Copyright: Crown
   

Help viewing PDFs:

Immediate action

Ref: MDA/2010/069 | Issued: 7 September 2010 at 13:00

  1. England
  2. Northern Ireland
  3. Scotland
  4. Wales
  5. Device
  6. Problem
  7. Action
  8. Distribution
  9. Manufacturer
  10. Feedback

If you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2010/069 or 2010/003/009/081/036

Technical aspects
Miss Feza Haque or Dr Crina Cacou or Mr Allan Hidderley
Medicines & Healthcare products Regulatory Agency
Market Towers 1 Nine Elms Lane
London
SW8 5NQ

Tel: 020 7084 3066 / 3338 / 3172
Fax: 020 7084 3106

Email: feza.haque@mhra.gsi.gov.ukcrina.cacou@mhra.gsi.gov.ukallan.hidderley@mhra.gsi.gov.uk

Clinical aspects
Dr Nicola Lennard
Medicines & Healthcare products Regulatory Agency
Market Towers
1 Nine Elms Lane
London
SW8 5NQ

Tel: 020 7084 3126
Fax: 020 7084 3111

Email: nicola.lennard@mhra.gsi.gov.uk

How to report adverse incidents
Please report via our website: Reporting adverse incidents involving medical devices.

Further information about CAS can be found on the Central Alerting System website (external link).

Alerts in Northern Ireland will continue to be distributed via the NI SABS system.

Enquiries and adverse incident reports in Northern Ireland should be addressed to:

Northern Ireland Adverse Incident Centre
Health Estates Investment Group
Room 17
Annex 6
Castle Buildings
Stormont Estate
Dundonald
BT4 3SQ

Tel: 02890 523 704
Fax: 02890 523 900

Email: NIAIC@dhsspsni.gov.uk

Northern Ireland Adverse Incident Centre (NIAIC) (external link)

How to report adverse incidents in Northern Ireland
Please report directly to NIAIC, further information can be found on the NIAIC website (external link).
Further information about SABS can be found on the SABS website (external link).

Enquiries and adverse incident reports in Scotland should be addressed to:

Incident Reporting and Investigation Centre
Health Facilities Scotland
NHS National Services Scotland
Gyle Square
1 South Gyle Crescent
Edinburgh
EH12 9EB

Tel: 0131 275 7575
Fax: 0131 314 0722

Email: nss.iric@nhs.net

Health Facilities Scotland - Incident Reporting and Investigation Centre (external link).

Enquiries in Wales should be addressed to:

Dr Sara Hayes
Senior Medical Officer
Medical Device Alerts
Welsh Assembly Government
Cathays Park
Cardiff
CF10 3NQ

Tel: 029 2082 3922

Email: Haz-Aic@wales.gsi.gov.uk

DePuy ASR™ hip replacement implants.

The DePuy ASR system consists of:

  • ASR acetabular cups for hip resurfacing arthroplasty or total hip replacement
  • ASR surface replacement heads for hip resurfacing arthroplasty
  • ASR XL femoral heads for total hip replacement.

DePuy ASR hip replacement implants have been in clinical use in the UK since 2003.

Recall of ASR hip replacement implants due to increased rates of revision.

The manufacturer has informed the MHRA that it is recalling all ASR hip replacement implants. Further background information on this recall is detailed in the manufacturer’s Field Safety Notice dated 24 August 2010. The manufacturer previously issued a Field Safety Notice on 08 March 2010.

The MHRA subsequently published a Medical Device Alert (MDA/2010/044) on 25 May 2010 providing advice for patient follow-up and to ensure that these devices are implanted in accordance with the manufacturer’s updated instructions for use (Revision C).

The manufacturer has now determined that the revision rate for all devices in the ASR systems at five years is higher than expected across the entire size range and so is recalling all ASR system hip replacement implants. Following consultation with our orthopaedic experts we are updating the advice provided in Medical Device Alert (MDA/2010/044) to ensure appropriate follow-up is considered for all patients already implanted with these hip replacement implants. This advice may change in light of any future developments.

  • Do not implant DePuy ASR hip replacements.
  • Return all unused ASR hip replacement implants to the manufacturer.
  • Inform all patients implanted with ASR hip replacements about this recall and schedule them for a follow-up visit.

Note: the recommendations in this MDA replace the advice given in MDA/2010/044.

  • Follow up all patients implanted with ASR hip replacements with clinical examination at least annually.
  • For patients presenting with symptoms of abnormal pain, limping, swelling around the hip, deteriorating hip function or radiological abnormality:
    • consider measuring cobalt and chromium ion levels in whole blood and/or performing cross sectional imaging including MRI or ultrasound scan
    • in line with MDA/2010/033, if metal ion levels in whole blood are elevated above 120 nmol/L (cobalt) or 135 nmol/L (chromium) [ie seven parts per billion (ppb) for either metal ion], a second test should be performed three months after the first in order to identify patients who require closer surveillance, which may include cross sectional imaging
    • if MRI or ultrasound scan reveals soft tissue reactions, fluid collections or tissue masses then consider revision surgery.

Note: Measurements of cobalt or chromium ions should be carried out:

This MDA has been distributed to:

  • NHS trusts in England (Chief Executives)
  • HSC trusts in Northern Ireland (Chief Executives)
  • NHS boards in Scotland (Chief Executives)
  • NHS boards and trusts in Wales (Chief Executives)
  • Care Quality Commission (Headquarters)
  • Primary care trusts in England (Chief Executives)

Onward distribution
Please bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:

Trusts to:
CAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:

  • Clinical governance leads
  • Medical directors
  • Nursing executive directors
  • Orthopaedic departments
  • Orthopaedic surgeons
  • Orthopaedic outpatient clinics
  • Outpatient theatre managers
  • Pathologists
  • Radiology departments
  • Radiology directors
  • Risk managers
  • Theatre managers

Care Quality Commission (CQC) (England only) to:
The MHRA considers this information to be important to:

  • Hospitals in the independent sector
  • Independent treatment centres
  • Private medical practitioners

Primary care trusts to:
CAS liaison officers for onward distribution to all relevant staff including:

  • Directors of public health
  • General practitioners (for information only)
  • NHS walk-in centres (for information only)

Paul Arnott
DePuy International Ltd
St Anthony’s Road
Leeds
LS11 8DT
England

Tel: 07771 971 930
Fax: 0113 387 6087

Email: parnott@its.jnj.com

If you have any comments or feedback on this Medical Device Alert, please email us at: dts@mhra.gsi.gov.uk 

Page last modified: 08 September 2010